Technology Listings


10 Results Sort By:
Small Molecules for Treating Cystic Fibrosis
ApplicationSmall molecule compounds to potentiate most common type of CFTR mutation in cystic fibrosis patients.Key BenefitsPotentiates ΔF508-hCFTR mutation, addressing more than 60 percent of CF patients. Market SummaryCystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and ion channel that malfunctions in the ge...
Published: 9/18/2017       Inventor(s): Nael Mccarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
Non-Nucleoside Inhibitors of the Measles and Nipah Viruses
Application A cell-based assay to screen for inhibitors of the measles virus (MV). Highly active compounds have been identified and analogs have been synthesized and evaluated. Key BenefitsPotent (sub-nM range), non-peptidic, non-nucleosidic compounds. Robust, cell-based, high-throughput screening assay. Technical Summary Vaccination serves as the ...
Published: 10/18/2016       Inventor(s): Richard Plemper, James Snyder, Aiming Sun
A Nutritional Therapy for Autism/Apraxia and Malabsorption
ApplicationAn elemental dietary supplement for treating autism, apraxia and malabsorption syndrome to reverse and avoid nutritional deficiencies. Key BenefitsProvides a complete elemental dietary supplement with the proper dosage of nutrients for children with the syndrome of allergy, apraxia, and malabsorption. Potential treatment for neuro & ...
Published: 2/17/2015       Inventor(s): Claudia Morris
Repurposed Drug for the Treatment of Nephrogenic Diabetes Insipidous
Application New use for metformin or other AMPK activators in treating nephrogenic diabetes insipidous (NDI). Key Benefits Lead candidate, metformin, is FDA-approved, safe, and currently in use for treating type II diabetes mellitus. There is no therapeutic available for NDI, current therapies only address symptoms. Repurposed metformin addresse...
Published: 8/15/2013       Inventor(s): Jeff Sands, Mitsi Blount, Janet Klein
Combination Drug Treatment for Neoplasms Associated with Tuberous Sclerosis
Application Combination of rapamycin and imatinib for the treatment of neoplasms associated with tuberous sclerosis (TS). Key Benefits Combined therapy shows 97% decrease in tumor volume in mouse model of TS compared to vehicle treatment. Dual therapy blocks two major signaling pathways implicated in TS. Market Summary Tuberous sclerosis (TS) is...
Published: 9/18/2012       Inventor(s): Jack Arbiser
Noscapine Analogs as a Potential Cancer Therapeutic
Application Noscapine analogs that incorporate 9-aminonoscapine for use as a cancer treatment. Key Benefits Has higher tubulin activity than noscapine. Induces apoptosis selectively in ovarian and T-cell lymphoma tumor cells that are already drug-resistant. Market Summary Ovarian cancer affects approximately 13 of every 100,000 women and about 8...
Published: 8/22/2012       Inventor(s): Harish Joshi, Ritu Aneja, Suryan Vangapandu
Drosophila Model of Galactosemia
Application Whole animal genetic model for Galactosemia. Fly model can be used to test efficacy of novel therapeutic interventions. Genetic system enables screening for suppressors and/or genetic modifiers of Galactosemia. Key Benefits First whole-animal genetic model to study GALT and GALE function. Only model that mimics acute...
Published: 4/14/2011       Inventor(s): Kenneth Moberg, Judith Fridovich-keil, Rebecca Sanders, Jennifer Sefton, Rebekah Kushner, Emily Ryan, Kerry Garza
Compounds for Suppressing Fragile X Premutation rCGG Repreat-Mediated Toxicity
Application Compounds for the treatment of Fragile X-associated tremor/ataxia syndrome. Key Benefits 11 known, FDA approved drugs identified that reduced rCGG-mediated lethality to a certain degree. 3 of these drugs also rescued locomotion deficits. Technical Summary Fragile X syndrome (FXS) is the most common inheritable form of cognitive disabi...
Published: 2/24/2011       Inventor(s): Peng Jin, Abrar Qurashi
Food Lists for Nutritional Management of Metabolic Disorders
ApplicationsBooklets which provide a reference guide for nutritional management of rare genetic diseases.Technical SummaryA majority of inherited metabolic disorders affect children and adults worldwide. Many metabolic disorders require special dietary therapy and monitoring by a team of physicians, nurses, genetic counsellors, social workers, and ...
Published: 4/29/2009       Inventor(s): Rani Singh
Compounds for the Treatment of Fragile X Syndrome and Methods of Screening
Application Small molecule compounds that may have therapeutic efficacy in Fragile X Syndrome and chemical genetic screens for potential drug targets. Technical Summary Fragile X Syndrome (FXS), the most common heritable form of mental retardation, is caused by transcriptional misregulation of the FMR1 gene and a subsequent loss of function of t...
Published: 2/24/2009       Inventor(s): Stephen Warren, Shuang Chang, Peng Jin